| COPD | Chronic obstructive pulmonary disease |
| CTCAE | Common Terminology Criteria for Adverse Events |
| PICOS | Population, Intervention, Comparison, Outcomes and Study framework for systematic reviews |
| SMD | Standardized mean differences |
| OR | Odds ratio |
| 95% CI | 95 percent confidence interval |
| RCTs | Randomized controlled trials |
| Mo | Morphine |
| Fent | Fentanyl |
| HyMo | Hydromorphone |
| Oxy | Oxycodone |
| po | Per oral |
| sc | Subcutaneous administration |
| tm | Transmucosal administration |
| Inhal | Inhalation |
| SAEs | Severe adverse reactions |
| NS | Not specified |
| HTA | Arterial hypertension |
| RR | Respiratory rate |
| SaO2 | Peripheral oxygen saturation |
| VAS | Visual analog scale for dyspnea |
| CPOT | Clinical pain observational tool |
| ECOG | Eastern Cooperative Oncology Group |
| NRS | Numeric rating scale |
| QoL | Quality of life |
| KPS | Karnofsky performance status |
| MEDD | Morphine equivalent daily dose |
| DOME | Daily oral morphine equivalent dose. Effective dose: Dose that reduced the intensity of dyspnea by at least 50%. |
| 6MWT | 6-min walk test |
| OTFC | Oral transmucosal fentanyl citrate |
| FBT | Fentanyl buccal tablet |
| FPNS | Fentanyl pectin nasal spray |